Finding cures for tropical diseases: Is open source an answer?

PLoS Medicine

Volumn 1, Issue , 2004, Pages 183-186

  Maurer, Stephen M ^a   Rai, Arti ^b   Sali, Andrej ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; METHYLTRANSFERASE;

AFRICAN TRYPANOSOMIASIS; CHAGAS DISEASE; COMPUTER PROGRAM; COST BENEFIT ANALYSIS; DRUG INDUSTRY; FEASIBILITY STUDY; FINANCIAL MANAGEMENT; LEISHMANIASIS; LICENCE; MALARIA; MEDICAL RESEARCH; PATENT; PROBLEM SOLVING; PROTEIN TARGETING; REVIEW; SARS CORONAVIRUS; TROPICAL DISEASE; VIRUS GENE; WORLD HEALTH ORGANIZATION; ARTICLE; DEVELOPING COUNTRY; DRUG COST; ECONOMICS; HUMAN; INTERNET; ORGANIZATION AND MANAGEMENT; PUBLIC RELATIONS; TROPICAL MEDICINE;

BIOMEDICAL RESEARCH; DEVELOPING COUNTRIES; DRUG COSTS; DRUG INDUSTRY; HUMANS; INTERNET; INTERPROFESSIONAL RELATIONS; PRIVATE SECTOR; RESEARCH SUPPORT AS TOPIC; TROPICAL MEDICINE;

EID: 15744364594     PISSN: 15491277     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pmed.0010056     Document Type: Review

References (17)

1. Trouiller O, Olliaro PL (1999) Drug development output from 1975 to 1996: What proportion for tropical diseases? Int J Infect Dis 3: 61-63.
2. Kremer M (2001) A purchasing commitment for new vaccines. Part II: Design Issues. In: Jaffe A, Lerner J, and Stern S, editors. Innovation policy and the economy. Boston: Massachusetts Institute of Technology. pp. 73-118.
3. Sachs J (1999 14 August) Helping the world's poorest. The Economist 352: 11-12.
4. Ganslandt M, Maskus K, Wong E (2001) Developing and distributing essential medicines to poor countries: The DEFEND proposal. The World Economy 24: 779-795.
5. Relman A, Angell M (2002 16 December) America's other drug problem. The New Republic: 27-41.
6. Pécoul B (2004) From pipeline to patients: Developing new drugs for neglected diseases. PLoS Med 1: e6.
7. Nwaka S, Ridley R (2003) Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat Rev Drug Discov 2: 919.
8. Hamilton D (2003 May 19) Open to all. Wall Street Journal; Sect R: 12.
9. von Grotthuss M, Wyrwicz LS, Rychlewski L (2003) mRNA cap-1 methyltransferase in the SARS genome. Cell 113: 701-702.
10. Sajid M, McKerrow JH (2002) Cysteine proteases of parasitic organisms. Mol Biochem Parasitol 120: 1-21.
11. Lerner J, Tirole J (2002) Some simple economics of open source. J Ind Econ 50: 197.
12. National Institute for Health Care Management Research and Educational Foundation (2002) Changing patterns of pharmaceutical innovation. Available: http://www.nihcm.org/innovations.pdf. Accessed 20 October 2004.
13. Rai AK (2005) Open and collaborative research: A new model for biomedicine. In: Hahn R, editor. Innovation in frontier industries: Biotech and software. Washington, (D.C.): AEI-Brookings Press. In press.
14. Normile D (2002) Syngenta agrees to wider release. Science 296: 1785.
15. J Smith (1991) Patenting the sun: Polio and the Salk vaccine. New York: Anchor/Doubleday. 416 p.
16. Oxford University Centre for Computational Drug Discovery. Screensaver lifesaver. Available at: http://www.chem.ox.ac.uk/curecancer.html. Accessed 20 October 2004.
17. Stanford University Pande Group. Genome@Home distributed computing. Available at: http://www.stanford.edu/group/pandegroup/genome. Accessed 20 October 2004.